Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €2.45 EUR
Change Today +0.006 / 0.25%
Volume 1.5K
AAQ On Other Exchanges
As of 6:36 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

aap implantate (AAQ) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/15/14 - €2.88
52 Week Low
10/29/14 - €2.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AAP IMPLANTATE (AAQ)

Related News

No related news articles were found.

aap implantate (AAQ) Related Businessweek News

No Related Businessweek News Found

aap implantate (AAQ) Details

aap Implantate AG, a medical device company, researches, develops, manufactures, and sells implants, medical instruments, bone cements, and replacement materials for orthopedics. It provides LOQTEQ, an anatomical angular stable plating system for compressing fractures with angular stable locking screws; and fragment set comprising T, L, quarter tubular, and reconstruction plates, as well as cortical and cancellous screws. It also offers cannulated screws for use in various fractures, as well as in anatomical regions; AcroPlate, which is used for the treatment of AC joint injuries; and autodynamic plating systems for secure fracture stabilization. In addition, the company provides a range of bone cements and accessories for application in arthroplasty, vertebroplasty, and kyphoplasty; and collagen fleeces for ambulant and stationary tissue care. Further, it offers bone substitutes that includes Artosal, a synthetic osteoconductive bone substitute; Cerabone, a ceramic bone substitute; OsteoCem, a calcium phosphate cement; Osnatal, a human bone allograft; and PerOssal, a synthetic bone substitute and carrier material. The company sells its products directly to hospitals, buying syndicates, and hospital groups, as well as through a network of distributors under the aap brand name; and to original equipment manufacturers and private label cooperations. It operates primarily in the European Union, Asia, and the United States. aap Implantate AG is headquartered in Berlin, Germany.

223 Employees
Last Reported Date: 05/15/15

aap implantate (AAQ) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €364.0K
Chief Finance Officer and Member of the Manag...
Total Annual Compensation: €252.0K
Compensation as of Fiscal Year 2014.

aap implantate (AAQ) Key Developments

aap Implantate AG Reports Sales Results for the Second Quarter and First Half of Fiscal Year 2015

aap Implantate AG reported sales results for the second quarter and first half of fiscal year 2015. For the quarter, the company generated sales totaling EUR 6.5 million against EUR 8.1 million a year ago. Total sales in the first half thus amounted to EUR 13.6 million against EUR 14.2 million a year ago.

aap Implantate AG Signs Several Agreements with US Distributors for the Distribution of its LOQTEQ(R) Products

aap Implantate AG has signed the first eight contracts for the distribution of its LOQTEQ(R) products with non-stocking distributors. On the basis of these agreements these distributors will cover different regions in the federal states California, Texas, Ohio, Tennessee, Oklahoma and Utah. The company anticipates initial sales in the US market in the third quarter of the current financial year. The company plans to sell its LOQTEQ(R) products locally through both stocking (distributor buys the products) and non-stocking distributors (distributor is supplied with the products and pays after usage). Most of the sales in the USA are handled through non-stocking distributors.

AAP Implantate AG Reports Earnings Results for the First Quarter Ended March 31, 2015

AAP Implantate AG has reported that net loss for the first quarter ended March 31, 2015 was EUR 456,000, or EUR 0.01 loss per share, compared to a net loss of EUR 368,000, or EUR 0.01 loss per share, for the same quarter ended March 31, 2014. Total revenue for the first quarter ended March 31, 2015 was EUR 8.15 million, compared to EUR 8.64 million for the same quarter ended March 31, 2014. Loss before tax for the first quarter ended March 31, 2015 was EUR 503,000, compared to a loss before tax of EUR 473,000 for the same quarter ended March 31, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AAQ:GR €2.45 EUR +0.006

AAQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AAQ.
View Industry Companies

Industry Analysis


Industry Average

Valuation AAQ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AAP IMPLANTATE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at